CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial
A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of the prostate-specific antigen (PSA) biomarker, one month after receiving MB-105 in a Phase 1 clinical trial. The promising initial data from Mustang Bio's investigational CAR T-cell therapy were shared at the 27th Annual Prostate Cancer Foundation Scientific Retreat, which was held virtually from Oct. 20–23. Tanya Dorff, MD, an oncologist at City of Hope National Medical Center in California, and the trial's principal investigator gave the presentation, titled "Clinical Development of PSCA-Targeted CAR T Cells for Advanced Prostate Cancer." The trial (NCT03873805) is actively recruiting adult mCRPC patients, who progressed while receiving a second-generation androgen receptor inhibitor, at the City of Hope center in Duarte. Additional data are expected by 2021. “We are encouraged by the initial data presented by C
Subscribe or to access all post and page content.